The calcium-sensing receptor (CaR) is the key controller of extracellular calcium (Ca 2+ o) homeostasis via its regulation of parathyroid hormone (PTH) secretion and renal Ca 2+ reabsorption. The CaR-selective calcimimetic drug Cinacalcet stimulates the CaR to suppress PTH secretion in chronic kidney disease and represents the world's first clinically available receptor positive allosteric modulator (PAM). Negative CaR allosteric modulators (NAMs), known as calcilytics, can increase PTH secretion and are being investigated as possible bone anabolic treatments against age-related osteoporosis. Here we address the current state of development and clinical use of a series of positive and negative CaR modulators. In addition, clinical CaR mutations and transgenic mice carrying tissue-specific CaR deletions have provided a novel understanding of the relative functional importance of CaR in both calciotropic tissues and those elsewhere in the body. The development of CaR-selective modulators and signalling reagents have provided us with a more detailed appreciation of how the CaR signals in vivo. Thus, both of these areas of CaR research will be reviewed.
Introduction
The principal physiological action of the CaR has been well defined in vivo, both in clinical studies of human CaR mutations (Thakker, 2004) , as well as in transgenic animal studies in which CaR is underexpressed in particular tissues (Ho et al., 1995; Chang et al., 2008) . The CaR (also commonly referred to as CaSR) has been given the provisional nomenclature CaS by NC-IUPHAR, but this should not be confused with the plant calcium receptor, CaS (Han et al., 2003; Tang et al., 2007; Vainonen et al., 2008) , with which the animal receptor bears no sequence or structural relation. CaR is a class C parathyroid hormone (PTH) secretion (Brown et al., 1993) , and the kidneys (Riccardi et al., 1998) , where CaR limits Ca 2+ reabsorption to protect against hypercalcaemia (Kantham et al., 2009) . Heterozygous, loss-of-function CaR mutation results in mild-to-moderate increases in PTH secretion (familial hypocalciuric hypercalcaemia, FHH), whereas homozygous loss-of-function CaR mutations can cause lifethreatening elevations in PTH secretion and blood calcium levels (neonatal severe hyperparathyroidism, NSHPT) (reviewed by Thakker, 2004; Egbuna and Brown, 2008 ). An FHH-like condition can also result from CaR autoantibodies (Kifor et al., 2003; Pallais et al., 2004; Brown, 2009 ) directed against the N-terminal region of the receptor's extracellular domain (ECD) as demonstrated using a phage-display library of CaR peptides (Kemp et al., 2009) . The original CaR (-/-) knockout mouse (produced by deleting CaR exon 5) displayed an NSHPT-like phenotype with greatly elevated neonatal PTH levels causing growth retardation and early death (Ho et al., 1995) . The heterozygous CaR knockout (+/-) more closely resembled FHH in humans with a more moderate increase in PTH secretion. The lethal rise in PTH secretion and blood calcium levels in these mice can be overcome in double knockout mice in which the CaR knockout is combined with either a PTH (-/-) knockout (Kos et al., 2003) , or, a Glial cell missing-2 (Gcm-2) (-/-) knockout in which the parathyroid glands fail to develop (Tu et al., 2003) . Again, this replicates the situation in humans whereby early parathyroidectomy in NSHPT saves the life of the infant.
In fact, the Exon-5 CaR knockout is a 'hypomorph' as it retains some function in cartilage (Rodriguez et al., 2005) , in keratinocyte (Oda et al., 2000) and lung (Finney et al., 2011) . Thus, an alternative murine model has been produced by deleting Exon-7, which knocks out the entire transmembrane region and intracellular domain (ICD), allowing for the transcription and translation of a non-functional secreted fragment corresponding to amino acid 1-577 of the ECD (Chang et al., 2008) . Indeed, a parathyroid-specific Exon-7 CaR knockout mouse exhibits even greater elevations in PTH levels (Chang et al., 2008) , that is an even more severe phenotype, than the partial Exon-5 CaR knockout (Ho et al., 1995) . Furthermore, in mice where the Exon-7 was selectively deleted from the osteoblasts, severe bone defects were observed thus demonstrating the specific role of CaR in bone, independent of its effects in parathyroid gland and kidney (Chang et al., 2008) .
Together, these in vivo observations demonstrate consistently the crucial role of CaR in maintaining stable blood calcium levels. This is further supported by clinical and transgenic studies in which CaR activity is elevated resulting in hypoparathyroid conditions and hypocalcaemia (Thakker, 2004; Egbuna and Brown, 2008) . Gain-of-function CaR mutations result in autosomal dominant hypocalcaemia (ADH) and many such gain-of-function (and indeed loss-offunction) CaR mutations have been collated at http:// www.casrdb.mcgill.ca/. These gain-of-function mutations are generally, although not exclusively, clustered either close to the two cysteine residues responsible for homodimerization, namely Cys-129 and 131 (Zhang et al., 2001) , or, in the transmembrane domain. Again, this condition can be mimicked by autoantibodies that bind the CaR except that here they elicit a gain-of-function effect by stabilizing activating conformations of the receptor (Brown, 2009 ). One such condition is autoimmune polyglandular syndrome type 1 (APS1) in which autoantibodies bind the N-terminal region of the CaR ECD leading to elevated CaR activity and thus hypoparathyroidism with characteristic hypocalcaemia and hyperphosphataemia (Brown, 2009; Kemp et al., 2009) . Furthermore, there are two mouse models of CaR gain-of-function; the first is the Nuf mouse, which expresses a CaR mutation (L723Q) resulting from a chemical mutagenesis study (Hough et al., 2004) . This mouse exhibits ectopic calcification, hypocalcaemia, hyperphosphataemia and inappropriately reduced levels of plasma PTH consistent with ADH in humans. In the second model, 5-point mutations were introduced to the CaR ECD but targeted to mature osteoblasts using the 3.5 kb osteocalcin promoter (Dvorak et al., 2007) . The resulting mouse displayed normal PTH and calcium levels but with enhanced bone resorption, further supporting a tissuespecific role for CaR in bone.
Calcium-sensing receptor pharmacology
Most GPCRs respond to modified amino acids or polypeptides making it possible to predict and define their agonist binding sites. However, for elemental calcium and CaR this has proven very difficult. The Hill coefficient for CaR indicates the cooperative binding of three to five Ca 2+ ions to the receptor (Bai, 2004) . It has long been recognized that clusters of negatively charged extracellular amino acids most likely account for CaR agonist binding; however, the lack of a solved 3D structure for CaR and the low affinity of Ca 2+ o binding have seriously hindered further investigation of this. Recent modelling work, employing the crystal structure for mGluR, has identified at least three (Huang et al., 2007) and as many as five potential Ca 2+ o binding sites in CaR (Huang et al., 2009b) . Two such regions, Gly222-Ile235 and Gly383-Ile408 (each containing five to six glutamate or aspartate residues) were individually inserted into a scaffold protein that exhibited no prior cation-binding capacity. Introduction of either of the two D/E-rich sequences gave the new protein the ability to bind calcium (Huang et al., 2007) . Furthermore, selective substitution of either Glu-224, Glu-228/229 or Glu398/399 for isoleucine each resulted in loss of CaR function supporting these observations. Indeed, the Glu398/ 399Ile mutation had perhaps the greatest effect at reducing CaR Ca 2+ o sensitivity and maximal response (Huang et al., 2007) . Such a steep agonist concentration/effect relationship is a critical feature of CaR function given the physiological necessity to maintain ionized serum Ca 2+ concentration between 1.1 and 1.3 mM. Even moderate hypocalcaemia or hypercalcaemia can cause altered neuromuscular activity leading to tetany or arrhythmias respectively. Therefore, further studies are necessary to elucidate the mechanistic basis for such cooperativity.
Studies of GPCR oligomerization challenge the notion that receptors always exhibit a simple linear relationship between receptor and ligand with a 1:1 stoichiometry (Park and Palczewski, 2005) . For instance, serotonin/glutamate receptor complexes respond to hallucinogenic drugs and are new potential drug targets for psychosis (Gonzalez-Maeso et al., 2008) . Furthermore, in cerebellar Purkinje cells, type B g-aminobutyric acid receptors (GABABR) and type 1 metabotropic glutamate receptor (mGluR1) colocalize in the dendritic spines of excitatory synapses. Here, conformational changes evoked by elevated Ca 2+ o concentration onto GABABR lead to a constitutive increase in the glutamate sensitivity of mGluR1 (Tabata et al., 2004) . The evidence that heterodimerization within group C GPCRs produces new types of receptors with entirely diverse pharmacological profiles has spurred a number of studies concerning CaR oligomerization. It has long been known that the CaR exists in the plasma membrane as a functional homodimer (Ward et al., 1998) , but there is more recent evidence that CaR may also oligomerize with other family C GPCR members. For instance, in hippocampal and cerebellar neurons, the CaR heterodimerizes not only with mGluR1a and mGluR5 ), but also with R1 and R2 GABAB receptors (Chang et al., 2007) . In both circumstances, formation of the heteromeric complex leads to profound changes in CaR expression levels, agonist sensitivity and cell signalling. Furthermore, CaR heterodimerization with other Group C GPCRs involved in nutrient sensing has been reported, which would allow for differential sensing of food intake (Wellendorph et al., 2010) .
Although Ca
2+
o-sensing is a crucial aspect of CaR function, many other divalent (Mg 2+ ), trivalent (lanthanides such as Gd 3+ ), polyvalent cations [e.g. poly-L-lysine, poly-arginine, protamine (Nemeth, 2002) ] and the aminoglycoside antibiotics (Ward et al., 2002; Gibbons et al., 2008) , are all agonists of the CaR (reviewed by Brown and MacLeod, 2001 ). These are orthosteric, type I agonists, in that they can activate the CaR in the absence of Ca 2+ o. In addition, compounds that modify the endogenous affinity of the receptor for Ca 2+ o, or allosteric modulators, have been identified. Some of these modulators are present in our body under physiological conditions including L-aromatic amino acids, glutathione, ionic strength and alkalinization (Bandyopadhyay et al., 2010) . For example, such type II agonists have been shown to produce biologically relevant effects such as the modulation of PTH secretion by dietary protein intake (Conigrave et al., 2004; Broadhead et al., 2010) , regulation of gastric function (Cheng et al., 1999) , cholecystokinin secretion (Liou et al., 2011) and alterations in urinary Ca 2+ o excretion (Riccardi and Brown, 2010) .
PTH plays an essential role in Ca 2+ o and inorganic phosphate (Pi) homeostasis and deviations in plasma PTH have a profound impact on mineral ion metabolism. For instance, prolonged increases in circulating PTH levels, such as those seen during primary hyperparathyroidism or hyperparathyroidism secondary to kidney failure, are associated with increase risks of cardiovascular morbidity and mortality (Block et al., 2004a) and activate bone-resorbing cells, the osteoclasts, causing net bone loss (Antonsen et al., 1998) . In contrast, short-lived bursts in plasma PTH activate boneforming cells, the osteoblasts, with an induction of bone formation markers and an improvement in bone mineral density in post-menopausal women (Dempster et al., 1993) . Therefore, in an ageing population, where the incidence of chronic kidney disease and osteoporosis are on the rise, manoeuvres aimed at modifying circulating plasma PTH represent an area of great therapeutic potential. As it was well established that the parathyroid CaR represents the master regulator of PTH secretion, the preclinical development of compounds that could modulate its secretion by the parathyroid glands was already ongoing even before the receptor was molecularly identified in 1993 (Nemeth, 2002; and other inorganic cations at the CaR (Brown et al., 1993) , it was unlikely that orthosteric ligands could provide the desired specificity and potency. Therefore, Nemeth and colleagues at NPS Pharmaceuticals, Inc., set out to identify compounds that could modify the concentration-response curves of the CaR for Ca
o. This approach proved to be successful, and led to the identification of two small organic molecules that can mimic Ca 2+ o or potentiate its receptor affinity, but that are not polycations. These ligands are termed 'type II calcimimetics', while orthosteric agonists are considered 'type I calcimimetics' (Nemeth et al., 1998) . On the other hand, compounds that reduce the CaR affinity for Ca 2+ o have also been identified and are named 'calcilytics' (Nemeth et al., 2001) . As for all positive allosteric modulators (PAM) and negative allosteric modulators (NAM), calcimimetics and calcilytics offer the advantage that: (i) they do not alter the plasma concentrations of the endogenous ligands, nor do they compete with them and bind to different sites from the orthosteric agonists; (ii) they enhance or inhibit endogenous physiological responses, that is, they do not evoke supramaximal ones or activate de novo signalling pathways; and (iii) their effects are saturable, that is, they are maximally active at EC50 values for Ca Table 1 .
Calcimimetics: positive CaR modulation and chronic kidney disease
Most current calcimimetics are phenylalkylamines and are derived from Ca 2+ channel blockers, such as verapamil or TMB-8 (Nemeth, 2002 ). An initial screening of this class of drug demonstrated that the calcium channel blocker fendiline could evoke a substantial mobilization of Ca 2+ i in isolated bovine parathyroid cells. Two of these compounds, NPS-467 and its chlorinated derivative, NPS-568, were identified and the racemic mixture separated into the R-and S-enantiomers for further pharmacological studies in bovine parathyroid cells. The R-enantiomer was shown to be 10-fold (NPS-568) or 100-fold (NPS-467) more potent than the S-enantiomer. Selectivity studies showed that, at concentrations below 10 mM, these two compounds did not activate nor affect the agonist responses of a variety of other GPCRs, including mGluRs. However, at high concentrations they did induce b adrenergic receptor-dependent second messenger production, an effect which is also mimicked by high (>5 mM) Ca 2+ o . Therefore, calcimimetics can evoke significant off-target pharmacology at high concentrations (>1 mM). However, specific effects on the CaR can be investigated by: (i) using drug concentrations at or below 1 mM; (ii) performing stereoselectivity experiments (the R-enantiomer being 10-to 100-fold more potent than the S-enantiomer); and (iii) using Ca 2+ o concentrations close to its EC50 value for the biological function to be assessed (as allosteric modulators, calcimimetics are ineffective at minimal and maximal Ca 2+ o concentrations -see above). It should be noted that when the calcimimetics are used outside of these experimental conditions, the resulting responses cannot be assumed to be true CaR-mediated events.
Calcimimetics are the first example of receptor PAMs to have received regulatory approval. Because extensive knowledge of the pharmacology of orthosteric and allosteric agonists in native parathyroid cells preceded the cloning of the CaR (Brown et al., 1993) , the calcimimetic Cinacalcet® received Food and Drug Administration (FDA) approval 11 years after the CaR was cloned. Marketed as Sensipar® in the USA, Mimpara in the EU and Regpara in Japan, the calcimimetics have been approved for the treatment of hyperparathyroidism secondary to chronic kidney disease (Block et al., 2004b) and for parathyroid carcinoma (Silverberg et al., 2007) . In addition, several other 'off label' applications have been reported in which Cinacalcet treatment aims at rectifying hypercalcaemic/hypophosphataemic states of various nature. These include, but are not limited to, hypercalcaemia after renal transplantation (Kruse et al., 2005) , lithiuminduced hyperparathyroidism (Sloand and Shelly, 2006) , X-linked hypophosphataemia (Alon et al., 2008) and oncogenic osteomalacia (Geller et al., 2007) . In addition, recent studies suggest the possibility of using calcimimetics to rescue CaR mutants, which result in protein misfolding (Huang et al., 2007) .
Calcimimetics bind to the transmembrane region of the CaR (Miedlich et al., 2002; Petrel et al., 2004) , and are believed to act by stabilizing CaR in an active state. In both rodent models and human subjects with end-stage chronic kidney disease, treatment with the marketed calcimimetic, Cinacalcet HCl, lowers PTH with the nadir after approximately 2-4 h, before PTH levels rise slowly again until~12 h post-dosing (Nemeth et al., 2004) . Studies in patients indicate that Cinacalcet treatment not only helps achieve the stringent targets set for an effective management of advanced chronic kidney disease, but it also provides a better control of plasma Pi and the calcium x inorganic phosphate (CaxPi) product, disturbances of which are associated with an increase in cardiovascular morbidity and mortality (Block et al., 1998; 2004a) . A recent prospective study carried out on a large cohort of dialysis patients over 26 months has demonstrated that calcimimetic treatment improves all-cause and cardiovascular survival (Block et al., 2010) .
The blood pressure-lowering effects of a high calcium diet in spontaneously hypertensive rats and humans has been known for more than 40 years (Ayachi, 1979) . However, it is only 14 years since the late Dr Bukoski first hypothesized that a CaR in the perivascular nerve network might provide the molecular transducer for the effects of hypercalcaemia on blood pressure (Bukoski et al., 1997) . These studies spurred a number of laboratories to elaborate on this initial idea, and thus identify the potential importance of the CaR in the vasculature. Thus, the existence of a functional CaR has been demonstrated in intact arteries , endothelial (Weston et al., 2005) and smooth muscle cells (Wonneberger et al., 2000; Smajilovic et al., 2006) and in intact human arteries (Molostvov et al., 2007; Alam et al., 2009) . As some patients with advanced chronic kidney disease also manifest with profound cardiovascular complications and most of them take Cinacalcet, we set out to investigate the role of the CaR and potential clinical utility of the calcimimetics in the vasculature. Our observations have shown that loss of CaR expression is associated with an increase in vascular calcification both in vitro and in vivo (Alam et al., 2009) , and that the calcimimetics delay smooth muscle cell calcification in vitro (Alam et al., 2009) . In addition, other investigators have shown that the calcimimetics appear to protect against the vascular remodelling, which occurs during advanced chronic kidney disease (Koleganova et al., 2009) and to delay calcification and atherosclerosis, which occur in apolipoprotein E-deficient mice (Ivanovski et al., 2009) , either alone or in combination with vitamin D (Rodriguez et al., 2008) . The first evidence of an effect of calcimimetics on the cardiovascular system in humans derives from a recent publication by Block et al. (2010) . In a prospective study involving a large cohort of patients with advanced chronic kidney disease which required haemodialysis, the authors have demonstrated that 2 year calcimimetic treatment reduces all-cause cardiovascular mortality. It remains to be determined whether these beneficial effects of calcimimetics on patient survival are mediated directly through the vascular CaR. Alternatively, they could be ascribed to calcium channel inhibition by these compounds (see above) or, as the recent literature seems to suggest, through inhibition of renin secretion by the juxtaglomerular apparatus of the kidney (Beierwaltes, 2010) , which would result in blood pressure reduction. While hypotensive effects of calcimimetics have been demonstrated in normal rats in vivo, they are not equally present in all blood vessel types (i.e. they are more prominent in the mesenteric, rather than the renal artery), tend to be detected at concentrations of the drug well above those used to inhibit PTH secretion and do not appear to be stereoselective. These studies suggest that the effect of the calcimimetics may be mediated through an inhibition of calcium channels, rather than to an activation of the CaR (Nakagawa et al., 2009) . The latter conclusion is supported by a recent study by Thakore and Ho (2011) , who also used a calcimimetic other than Cinacalcet, namely calindol, and that ascribed its vasorelaxant properties to L-type Ca 2+ channel blockade. Whatever their molecular target (i.e. whether Ca 2+ channel inhibition or CaR activation), the improvement of all-cause mortality by calcimimetics in patients with advanced chronic kidney disease reported in the Block et al. (2010) study remains a significant positive side-effect of these drugs. A randomized clinical trial in haemodialysis patients taking Cinacalcet is now due and it will no doubt shed light on the potential vasorelaxant effects of this drug.
The relative therapeutic success of Cinacalcet has lead to the development of other calcimimetic compounds, for example the structurally novel benzothiazole compounds reported recently by Acadia Pharmaceuticals (Ma et al., 2011) . These compounds reportedly exhibit greater CaSR potency than the phenylalkylamine calcimimetics, at least in vitro, and may have a different binding site (Ma et al., 2011) .
Calcilytics: negative modulation and osteoporosis
PTH is a potent regulator of skeletal metabolism owing to its unique pharmacokinetic profile, which allows this hormone to evoke both anabolic and catabolic effects (Rizzoli et al., 1992) . It is the osteoanabolic action of this hormone, which has led to the testing of intact PTH (1-84, Preos/Preotact) or one of its biologically active fragments (1-34, Forteo) in preclinical models of hormone-deficient bone loss and, subsequently, in post-menopausal women. On the basis of the ability to reduce fracture risk and to increase bone mineral density (Rittmaster et al., 2000; Neer et al., 2001; Greenspan et al., 2007) , PTH (1-34) and intact PTH (1-84) were granted FDA and European Medicines Agency (EMEA) approval to treat hormone-deficient osteoporosis in 2002 and 2006 respectively. However, PTH treatment carries a 'black box' label and has only been approved for 2 years based on the evidence that it increased the risk of osteosarcoma in rats (Vahle et al., 2002) . These findings, together with an inconvenient route of administration (daily subcutaneous injections) and the elevated costs, suggested that identification of specific, potent CaR antagonists capable of evoking endogenous bursts in plasma PTH could overcome some of the issues associated with exogenous PTH treatment. If successful, this strategy has the additional advantage that CaR modulation can only evoke changes in plasma PTH within the physiological range, rather than supra-maximal effects potentially achieved with exogenous PTH administration. At the same time as the calcimimetic studies were carried out, NPS Pharmaceuticals, Inc., together with the then SmithKline Beecham (now GlaxoSmithKline) had already initiated a drug discovery programme for the identification of pharmacological inhibitors of the CaR (Nemeth, 2002) , which could evoke bone anabolic effects without inducing sustained PTHdependent bone loss. That is, the ideal drug had to achieve rapid plasma PTH C MAX, followed by a rapid return to baseline levels shortly after administration of the compound (Nemeth, 2002) .
A first screen identified a weak CaR antagonist, which had off-target pharmacology at the b-adrenoceptors, the cardiac human ether-a-go-go related gene (hHERG) ion channel and cytochrome P450 2D6 (CYP2D6) (Nemeth et al., 2001; Marquis et al., 2009b) . Subsequent modifications of this compound yielded the first calcilytic, NPS-2143, an orally active compound with greater potency and specificity for the CaR (Nemeth et al., 2001; Marquis et al., 2009a) .
Mutagenesis and homology modelling studies have subsequently demonstrated that the calcilytic binding site is located within the transmembrane domain of the CaR molecule, where it partly overlaps with the calcimimetic (NPS-R568) binding site (Miedlich et al., 2004) . Initial functional studies carried out in recombinant systems demonstrated that NPS-2143 suppressed CaR activity. In vivo, NPS-2143 altered plasma PTH levels with a good overlap with its in vitro potency, with EC50 values of~40 nM (Nemeth et al., 2001) . Treating rats with NPS-2143 evoked an increase in plasma PTH which was comparable to that observed following exogenous PTH administration (Nemeth et al., 2001) . These in vivo effects on plasma PTH have never been tested for other calcilytics, including Calhex 231 (Petrel et al., 2003; Kessler et al., 2006) , for which the therapeutic benefits are unknown, as thus far efficacy, potency and safety studies in vivo are unavailable.
Following NPS-2143 treatment bone mineral density did not increase, due to the long half-life of NPS-2143, which resulted in an increase in plasma PTH, a bone catabolic stimulus. In support of this hypothesis, blocking the sustained, PTH osteocatabolic effects with estrogens resulted in formation of new bone (Gowen et al., 2000) . Thus, these observations suggested feasibility in producing short bursts in plasma PTH as an anti-osteoporotic treatment, an effect that could be achieved by rapid and transient inhibition of the parathyroid CaR. Efforts to improve the pharmacokinetics of this amino alcohol chemotype led to the identification of compounds with better PK, but with poor oral bioavailability. To obviate this problem, a 'pro-drug' approach was used. An esteric form of NPS-2143 was produced (SB-423557) which, following a rapid absorption, was quickly cleaved into the free acid form (SB-423562) before entering the systemic circulation (Nemeth, 2008) . In a rat model of osteoporosis, treatment with SB-423557 caused a transient increase (two-to threefold) in plasma PTH concentration, which was maximal after 20 min and that had returned to baseline 2 h post-treatment (Kumar et al., 2010) . These effects were accompanied by an increase in bone mineral density and an activation of markers of bone formation. Early clinical studies in healthy volunteers infused with the pro-drug or free acid showed a dosedependent increase in plasma PTH of twofold or greater for up to 8 h, and that SB-423557 was safe and well tolerated (Kumar et al., 2010) .
Further developments have led to the synthesis of another orally bioavailable amino alcohol chemotype, ronacaleret hydrochloride (SB-751689) (Nemeth, 2008) , with improved specificity and pharmacokinetic profiles. Although ronacaleret reached phase 2 and treatment in postmenopausal women did activate bone turnover markers, its development was terminated in 2008 due to lack of efficacy (Balan et al., 2009) .
Subsequent screening of an internal compound library at Novartis led to the identification of compound '2a', which, following a series of optimization steps to improve its PK, led to 1H-quinazolin-2-ones derivatives which were found to act as calcilytics. Of these, the orally bioavailable compounds '7h' and '11m' evoked a very rapid (within minutes) and short-lasting (an hour or so) peak in plasma PTH at subnanomolar concentrations (Widler et al., 2010) . While these observations sound promising, clinical studies are necessary to assess the efficacy, potency and safety profiles of these compounds.
Recently Japan Tobacco Inc. has synthesized a novel calcilytic, JTT-305 (now licensed to Merck, Inc., as MK-5442) (Balan et al., 2009) . It is a similar chemotype of ronacaleret and, in phase 2 clinical trials, it shows a significant improvement of bone mineral density (Fukumoto, 2011) .
Calcium-sensing receptor-mediated intracellular signalling
The CaR exhibits pleiotropic interaction with Gaq/11, Gai/o and Ga12/13 in a variety of cell types (reviewed in Ward, 2004; Khan and Conigrave, 2009; Magno et al., 2010) and even to Gas in mammary epithelial tumour cells (Mamillapalli et al., 2008; Magno et al., 2010) and murine pituitary corticotrophderived, AtT-20 cells (Mamillapalli and Wysolmerski, 2010) . Such apparent promiscuity may be necessary to provide selective regulation of the wide array of cellular effects associated with the CaR both within and without the calcium homeostatic system. Such interactions may be cell-and contextdependent; however, it is nevertheless possible to identify particular pathways as being responsible for mediating certain CaR functions. For example, in mice lacking either Ga q or Ga11 in their parathyroid glands, there is a modest increase in PTH secretion; however, where both Gaq and Ga11 are missing, PTH levels are greatly elevated (Wettschureck et al., 2007) . Therefore, it would appear that, for PTH secretion control at least, CaR-induced Gaq/11 activation contributes significantly to the response.
Calcium-sensing receptor-induced Ca

2+ i oscillations
To understand the mechanism of CaR-mediated signalling we must look at the activity of the receptor in individual cells. Ca (Bruce et al., 1999; Davies et al., 2007) as well as developing mathematical descriptions of the oscillations (Szekely et al., 2009 (Nemeth et al., 2004) . CaR-induced Ca 2+ i mobilization has also been reported in parathyroid cells (Ridefelt et al., 1995) and other cell types where CaR is expressed endogenously (Shorte et al., 1995; Adebanjo et al., 1998; Ward et al., 2002) and thus a number of studies have explored the mechanistic basis and functional consequences of CaR-induced Ca 2+ i oscillations.
Phosphorylation of the CaR intracellular tail regulates receptor activity
Most CaR-HEK cell studies employ baseline Ca Davies et al., 2006; (Figure 1 ). It should be noted that the actual concentrations at which these 'transitions' occur are subject to multiple factors such as temperature, receptor expression levels and buffer ingredients but the trend is broadly true under most conditions. What is interesting is that the linear part of the Ca 2+ o concentration-effect curve comprises each of these response types and thus any signal or condition that may independently modulate oscillation frequency will tend to alter the EC50 accordingly without necessarily affecting agonist binding. This is interesting both from a molecular perspective and also as a means of altering CaR efficacy. The single most important CaR residue for controlling these oscillations is threonine-888 (in humans) and this serves as a highly conserved protein kinase C phosphorylation site. Cloning and sequencing of the bovine CaR and then human CaR, revealed at least five conserved PKC consensus sequences in the intracellular loops (T646 and S794) and intracellular tail (T888, S895 and S915) of the receptor. Mutating each putative PKC site in turn to a non-phosphorylatable residue, Bai et al. (1998b) found that the two intracellular loop residues do not contribute to regulation of CaR Ca 2+ o sensitivity and that mutation of residues S895 and S915 elicit only modest effects on the EC50 for Ca 2+ o or on responsiveness to the phorbol ester phorbol-12-myristate-13-acetate (PMA). In contrast, mutation of T888 (to valine) elicited a substantial leftward shift in the Ca (Jiang et al., 2002) . Together, these data suggested that CaR T888 is central to the control of CaR signalling. This idea was advanced by single cell imaging which revealed that CaR T888A tends to elicit sustained rather than oscillatory Ca 2+ i mobilization which can be mimicked in cells expressing wild-type CaR by inhibiting PKC. This suggested that for each Ca 2+ i oscillation, PKC-mediated phosphorylation on CaR T888 terminated the Ca 2+ i mobilization caused by receptor activation (Figure 2 ) and a phospho-specific antibody for CaR T888 did indeed reveal that CaR can be phosphorylated by PKC in that way (Davies et al., 2007) . The concept of dynamic phosphorylation as a mechanism of class C GPCR regulation was first proposed by Nash et al. (2001; 2002) with specific regard to the metabotropic glutamate receptor mGluR5. The residue phosphorylated dynamically in this case is mGluR5 S839 (Kim et al., 2005) , this residue being 13 amino acids closer to the transmembrane region than CaR T888 . Indeed, there are both interesting parallels as well as specific differences between the dynamic phosphorylation of the two receptors.
CaR
T888 dephosphorylation shapes downstream signalling
There is a significant problem, however, with the idea that CaR activation leads to CaR T888 phosphorylation and thus to receptor inhibition. The most striking problem is that at the top end of the Ca 2+ o concentration effect curve, the responses of single cells tend to change from oscillatory into sustained, whereas one might expect their CaRs to be maximally phosphorylated and thus maximally inhibited. (2010) . This bar is intended to indicate the heterogeneity of the cellular responses at each concentration (see also Nash et al., 2002 (McCormick et al., 2010) . In contrast, the L-aromatic amino acids (10 mM; lower potency PAM) elicited sustained CaR T888 phosphorylation and oscillatory Ca The identity of the phosphatase responsible remains unknown although some evidence points towards PP2A being involved. For example, the PP1/PP2A inhibitor calyculin-A prevents dephosphorylation of CaR T888 and inhibits CaR-induced Ca 2+ i mobilization in CaR-HEK and PT cells and abolishes the inhibitory effect of CaR on PTH secretion in human isolated PT cells. Furthermore, PP2A catalytic subunit colocalizes with phosphorylated CaR and PP2A activity is elevated following CaR activation in HEK-293 cells (Davies et al., 2007; McCormick et al., 2010) .
Together, this model of differential CaR T888 phosphorylation explains both the suppressive effect of phorbol esters and calyculin-A and stimulatory effect of PKC inhibition on CaRinduced Ca 2+ i mobilization (Figure 2) , and the transition from oscillatory to sustained CaR signalling (Figure 1 ). (Lazarus et al., 2010) . The index case and his father both exhibited hypocalcaemia, inappropriately normal PTH concentrations and relative hypercalciuria typical of ADH. When recapitulated in vitro, CaR T888M exhibited a leftward shift in Ca 2+ o concentration dependence and resistance to signalling inhibition by PMA (Lazarus et al., 2010) . This would suggest that, under normal conditions, the human CaR is subject to feedback inhibition by phosphorylation on Thr-888 raising the possibility that PTH secretion and thus Ca nalling. Together, these molecular and clinical data explain functional observations first made~20 years ago showing that phorbol esters inhibit the suppressive effects of high Ca 2+ o concentration on PTH secretion (Nemeth et al., 1986; Kobayashi et al., 1988; Morrissey, 1988; Membreno et al., 1989) .
Mitogen-activated protein kinase activation
CaR is known to activate an array of protein kinase pathways most notably the mitogen-activated protein (MAP) kinases ERK and p38 MAPK (reviewed in Ward, 2004; Khan and Conigrave, 2009; Magno et al., 2010) . The mechanism of CaR-induced ERK activation, at least in culture, involves triple-pass signalling whereby CaR stimulates an extracellular matrix metalloproteinase to elicit the extracellular release of an EGF-like peptide, which then stimulates EGF receptor (EGFR)-mediated signalling . In CaRexpressing HEK-293 cells, chronic receptor activation stimulates PTH-related protein (PTHrP) secretion into the medium , an effect also observed in PC-3 human prostate cancer cells and H-500 rat Leydig cells (Sanders et al., 2000) , and in each case the release of PTHrP is dependent on ERK activation resulting from transactivation of the EGFR . Similarly, matrix metalloproteinase and EGFR activation also result from CaR activation in human MCF-7 breast cancer cells (El Hiani et al., 2009) . Indeed, this mechanism may contribute to the putative oncogenic effects of CaR in breast and prostate cancerswhereas CaR is associated with tumour suppression in colon and parathyroid tumours (Saidak et al., 2009 ).
Calcium-sensing receptor and the cytoskeleton
Another possible mechanism by which the CaR might limit PTH secretion is to attenuate the trafficking of secretory granules through the cytoskeletal network. The exocytotic barrier function of cortical actin has been described in endocrine cells such as adrenal chromaffin cells and pancreatic betacells (Burgoyne and Morgan, 2003) but may also exist in parathyroid cells (Quinn et al., 2007) . Significantly, the cortical actin barrier is not simply a constitutive brake on secretion but can be regulated via extracellular signals causing actin assembly/disassembly (Burgoyne and Morgan, 2003) . In dispersed bovine parathyroid cells, the filamentous actinsevering compounds, latrunculin and cytochalasin, permitted increased PTH secretion, whereas the actin polymerizing agent, jasplakinolide, substantially inhibited PTH secretion (Quinn et al., 2007) . In addition, CaR activation elicits r-mediated actin filament formation in HEK-293 cells (Davies et al., 2006) and thus could be directly involved in cytoskeletal alteration as a mechanism for secretory modulation. This idea is further supported by the fact that CaR binds the cytoskeletal protein filamin-A, via the receptor's ICD and disruption of this interaction inhibits CaR-mediated ERK activation (Hjalm et al., 2001) . Also, CaR-induced Ga 12/13 and r activation has been reported in Madin-Darby canine kidney cells (Huang et al., 2004) and in breast cancer cells (Huang et al., 2009a) . Together, Ga12/13 proteins have been implicated in a variety of cellular functions including regulation of platelet activation and smooth muscle contraction, as well as embryonic angiogenesis, cell migration in the immune system and metastatic spread in tumour cells (Worzfeld et al., 2008) . Therefore, it will be interesting to determine the extent to which CaR-induced Ga12/13 activation may influence these processes in cells in which the CaR is expressed.
Conclusions
Because of their ability to modulate PTH secretion, CaR-based therapeutics constitute an important and novel toolkit for the treatment of disturbances in Ca 2+ o metabolism. Calcimimetics are the first class of receptor PAMs on the market and are being used increasingly for the treatment of hyperparathyroidism and of other hypercalcaemic disorders. Indeed, recent clinical observations suggest that they also ameliorate cardiovascular complications associated with advanced chronic kidney disease and might allow for a reduction in vascular calcification and an improvement in blood pressure control in patients suffering from this disease. As for calcilytics, they improve bone mineral density and induce markers of bone formation in ovariectomized rats and have reached phase III clinical trials for the treatment of post-menopausal osteoporosis, a disease which affects 1:3 women and 1:10 men above the age of 50, worldwide. Finally, basic science research has made significant advances in understanding CaR-mediated cell signalling in vivo. Further studies must go hand-in-hand with these drug discovery programmes to establish how best to achieve an inhibition of the CaR to mobilize the pool of PTH-containing vesicles, in order to evoke short-lived osteoanabolic bursts of this hormone without its undesired effects on bone breakdown.
